Neurostimulation – our new study reveals trends, R&D progress, and predicted revenues Where is the Neurostimulation market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead Our 178-page report provides 102 tables, charts, and graphs, providing over 2900 unique datapoints. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Neurostimulation market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are forecasts for 6 Neurostimulation Products and 7 Neurostimulation Applications, each forecasted at a global, regional and national level.
Neurostimulation, by Application • Pain Management • Epilepsy • Urinary and Fecal Incontinence • Hearing Loss • Gastroparesis • Parkinson’s Disease • Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 10 leading national markets: • North America: • The US • Canada
• Europe: • Germany • The UK • Italy • Spain • France • Rest of Europe
• APAC: • Japan • China • India • Rest of Asia-Pacific
• RoW: • Latin America • Middle East and Africa • Other Countries
The report also includes profiles and for some of the leading companies in the Neurostimulation market, with a focus on the Neurostimulation segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, China, India and the US in particular, will continue to achieve high revenue growth to 2027.
Leading companies and the potential for market growth Overall world revenue for Neurostimulation will surpass $19bn in 2027, our work calculates. We predict strong revenue growth through to 2027. With increasing incidence of neurological diseases, the demand for neurostimulation devices is expected to increase significantly in the next few years.
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Neurostimulation Market report helps you In summary, our 178-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the Neurostimulation market and 2 different segmentations, with forecasts for 6 Products and 7 Applications at a Global, Regional and National level – discover the industry’s prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 6 regional and 10 key national markets – North America, Europe, Asia-Pacific, Latin America, Middle East and Africa are forecasted, as well as the US, Canada, Germany, France, the UK, Italy, Spain, Japan, China, India, • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market – including company profiles for 10 companies involved in the Neurostimulation market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Neurostimulation market and leading companies. You will find data, trends and predictions.
Get our report today Neurostimulation Devices Market 2017-2027: Forecasts by Product (Spinal Cord Stimulators, Deep Brain Stimulators, Vagus Nerve Stimulators, Sacral Nerve Stimulators, Cortical Stimulators and Others), by Application (Epilepsy, Pain Management, Hearing Loss, Incontinence, Gastroparesis, Parkinson’s Disease and Others) and Geography. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Why You Should Read This Report 1.2 How This Report Delivers 1.3 Key Questions Answered by This Analytical Report Include: 1.4 Who is This Report For? 1.5 Methodology 1.5.1 Primary Research 1.5.2 Secondary Research 1.5.3 Market Evaluation & Forecasting Methodology 1.6 Frequently Asked Questions (FAQ) 1.7 Associated Visiongain Reports 1.8 About Visiongain
2. Introduction to the Neurostimulation Devices Market 2.1 Classification of Neurostimulation Devices 2.2 What are Neurostimulation Devices? 2.3 Regulation of Medical Devices? 2.3.1 The US Approval and Regulation System 2.3.2 The EU Approval and Regulation System 2.3.3 China Approval and Regulation System 2.3.4 Japan Approval and Regulation System 2.3.5 India Approval and Regulation System
3. Neurostimulation Devices Market: Drivers & Restraints 3.1 Driving Factors 3.1.1 Growing prevalence of neurological disorders 3.1.2 Increasing Growth of Aging Population 3.1.3 Changing Lifestyle and growing obesity 3.1.4 Various opportunities from emerging markets 3.2 Market Restraints 3.2.1 Shortage of neurologists to treat an increasing number of neurologic patients 3.2.2 Uncertain outcomes of changing healthcare policies 3.2.3 Imposition of the medical device excise tax in the U.S. 3.2.4 Poor primary healthcare infrastructure and lack of healthcare insurance in developing countries
8. The Global Neurostimulation Devices Market, Competitive Landscape 8.1 New Product Launches 8.2 Acquisitions, Collaborations, and Partnerships 8.3 Other Developments
9. Conclusions 9.1 Top Neurostimulation Devices Market 9.2 Top Neurostimulation Devices Applications Market 9.3 Top Nations Neurostimulation in the Devices Market
10. Glossary Associated Visiongain Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Figures Figure 2.1 Neurostimulation Devices Market Segmentation Figure 2.2 Stages of regulatory control Figure 3.1 Neurostimulation Devices Market: Drivers and Restraints, 2017-202 Figure 3.2 Share of geriatric population, by region, 2010-2020 Figure 4.1 Neurostimulation Devices Submarkets by Product: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 4.2 Spinal Cord Stimulators Devices Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 4.3 Deep Brain Stimulators Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 4.4 Vagus Nerve Stimulators Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 4.5 Sacral Nerve Stimulators Devices Markets by Region: Forecast ($m), 2017-2027 Figure 4.6 Cortical Stimulators by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 4.7 Other Neurostimulation Devices Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 5.1 Neurostimulation Devices Markets by Application: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 5.2 Epilepsy Neurostimulation Devices Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 5.3 Pain Management Neurostimulation Devices Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 5.4 Hearing Loss Neurostimulation Devices Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 5.6 Urinary and Fecal Incontinence Neurostimulation Devices Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 5.7 Gastroparesis Neurostimulation devices Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 5.8 Parkinson’s Disease Neurostimulation Devices Markets by Region: Forecast Revenue ($m) and CAGR (%) 2017-2027 Figure 5.9 Other Neurostimulation Devices Markets by Region: Forecast ($m), 2017-2027 Figure 6.1 Neurostimulation Devices Markets by Region: Forecast ($m), 2016 Figure 6.2 North America Neurostimulation Devices Markets by Country (%), 2017 Figure 6.3 U.S. Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.4 Increasing Prevalence Rate In Canada By Chronic Diseases, 2001-2039 Figure 6.5 Canada Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.6 Europe Neurostimulation Devices Markets by Country (%), 2017 Figure 6.7 Change in population structure in Germany, 1995-2015 Figure 6.8 Germany Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.9 France Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.10 U.K. Population estimates and projections, 2010-2040 Figure 6.11 U.K. Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.12 Italy Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.13 Spain Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.14 Asia-Pacific Neurostimulation Devices Markets by Country (%), 2017 Figure 6.15 Japan Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.16 Share of Aging population in total Chinese population, 2011-2016 (%) Figure 6.17 China Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.18 India Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.19 Rest of the World Neurostimulation Devices Markets by Region (%), 2017 Figure 6.20 Latin America Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 6.21 Middle East and Africa Revenue Neurostimulation Devices Revenue ($m) and AGR (%) 2017-2027 Figure 7.1 Advanced Bionics: Recent Financials, 2014-2016 Figure 7.2 Boston Scientific Corporation: Recent Financials, 2014-2016 Figure 7.3 Cochlear: Recent Financials, 2014-2016 Figure 7.4 Cyberonics: Recent Financials, 2014-2016 Figure 7.5 Medtronic: Recent Financials, 2014-2016 Figure 7.6 Nevro Corp: Recent Financials, 2014-2016 Figure 7.7 St. Jude Medical: Recent Financials, 2013-2015 Figure 9.1 Top Neurostimulation Devices Market Figure 9.2Top Neurostimulation Devices Applications Figure 9.3 Top Nations in the Neurostimulation Devices Market
List of Tables Table 4.1 Neurostimulation Devices Submarkets by Product: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 4.2 Spinal Cord Stimulators Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 4.3 Deep Brain Stimulators by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 4.4 Vagus Nerve Stimulators Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 4.5 Sacral Nerve Stimulators Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 4.6 Cortical Stimulators Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 4.7 Other Neurostimulation devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 5.1 Neurostimulation devices Markets by Application: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 5.2 Epilepsy Neurostimulation Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 5.3 Pain Management Neurostimulation Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 5.4 Hearing Loss Neurostimulation Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 5.6 Urinary and Fecal Incontinence Neurostimulation Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 5.7 Gastroparesis Neurostimulation Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 5.8 Parkinson’s Disease Neurostimulation Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 5.9 Other Neurostimulation Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.1 Neurostimulation Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.2 North America Neurostimulation Devices Markets by Country: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.3 North America Neurostimulation Devices Markets by Product: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.4 North America Neurostimulation Devices Markets by Application: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.5 Europe Neurostimulation Devices Markets by Country: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.6 Europe Neurostimulation Devices Markets by Product: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.7 Europe Neurostimulation Devices Markets by Application: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.8 Asia-Pacific Neurostimulation Devices Markets by Country: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.9 Asia-PacificNeurostimulation Devices Markets by Product: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.10 Asia-PacificNeurostimulation Devices Markets by Application: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.11 Rest of the World Neurostimulation Devices Markets by Region: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.12 Rest of the World Neurostimulation Devices Markets by Product: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 6.13 Rest of the World Neurostimulation Devices Markets by Application: Forecast ($m, AGR%, CAGR%), 2017-2027 Table 7.1 Advanced Bionics Product Portfolio Table 7.2 Advanced Bionics: Developments Table 7.3 Boston Scientific Corporation: Product Portfolio Table 7.4 Boston Scientific Corporation: Developments Table 7.5 Cochlear Ltd.: Product Portfolio Table 7.6 Cochlear Ltd.: Developments Table 7.7 Cyberonics.: Product Portfolio Table 7.8 Cyberonics: Developments Table 7.9 Medtronic: Product Portfolio Table 7.10 Medtronic: Developments Table 7.11 Neuronetics: Product Portfolio Table 7.12 Neuronetics: Developments Table 7.13 Nevro Corp: Product Portfolio Table 7.14 Nevro Corp: Developments Table 7.15 Cogentix Medical: Product Portfolio Table 7.16 Cogentix Medical: Developments Table 7.17 St. Jude Medical: Product Portfolio Table 7.18 St. Jude Medical: Developments Table 7.19 NDI Medical: Product Portfolio Table 7.20 NDI Medical: Developments Table 7.21 Other Companies in the Neurostimulation Devices Market Table 7.21 Other Companies in the Neurostimulation Devices Market (continued) Table 7.21 Other Companies in the Neurostimulation Devices Market (continued) Table 7.21 Other Companies in the Neurostimulation Devices Market (continued) Table 7.21 Other Companies in the Neurostimulation Devices Market (continued) Table 8.1 New Product Launches Table 8.2 Acquisitions, Collaborations, and Partnerships Table 8.3 Other Developments
480 Biomedical Inc. Abbott Laboratories Accellent Advanced Bionics, LLC Advanced Neuromodulation Systems Allergan Plc Anterios, Inc. Argon Medical Devices Inc. B. Braun Baxter International, Inc. Bayer AG BioControl Medical (B.C.M) Ltd. BIOMED CENTRAL LTD Bionx Medical Technologies Inc. Boston Scientific Corporation Canadian Institutes of Health Research Carestream Health, Inc. Cochlear Ltd. Codman & Shurtleff, Inc. Cogentix Medical Cyberonics Inc. Deep Brain Innovations Edwards Lifesciences Corp. EndoStim Inc. EnteroMedics Inc GE HEALTHCARE LTD Globus Medical, Inc. Helius Medical Technologies, Inc. Hitachi Health Care Manufacturing K.K. Hologic, Inc. Inspire Medical Systems Inc. IntraPace, Inc. Johnson & Johnson Johnson & Johnson Medical Limited LifeTech Scientific Corp. LivaNova PLC Mainstay Medical International Plc MED-EL Medtronic Plc Medtronic Usa Inc. Mindray Medical International Ltd. Natus Medical, Inc. NDI Medical LLC Neurologica Corp. NeuroMetrix, Inc. Neuronetics, Inc. NeuroPace, Inc. NeuroSigma, Inc. Nevro Corp Nexstim Oyj Penumbra, Inc. Pfizer Inc. Quest Diagnostics Roche Holding AG Royal Philips NV Siemens AG Smith & Nephew Plc Soterix Medical Inc St. Jude Medical Stryker Corp. Synapse Biomedical Inc. Terumo Corp. Tesla, Inc. Toshiba Medical Systems Corporation XOGRAPH HEALTHCARE LTD Zimmer Biomet Holdings, Inc.
List of Organisations American Academy of Neurology Chinese Food & Drug Administration (CFDA) Federal Interagency Forum on Aging-Related Statistics Food & Drug Administration (US) International Labour Organization (ILO) Ministry of Health, Labor and Welfare (MHLW) National Health Service (UK) Parkinson’s Disease Foundation World Health Organisation (WHO)
Download sample pages
Complete the form below to download your free sample pages for Neurostimulation Devices Market 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
